FDA Approves Supplemental Application for KALETRA by AbbVie
The FDA has approved a supplemental application for KALETRA, a combination of Lopinavir and Ritonavir, submitted by AbbVie.
Asset / Drug
Drug and asset intelligence for KALETRA with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.